Candriam Luxembourg S.C.A. increased its stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 89.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 227,000 shares of the specialty pharmaceutical company’s stock after buying an additional 107,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.83% of Paratek Pharmaceuticals worth $5,471,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. American International Group Inc. increased its stake in Paratek Pharmaceuticals by 34.1% in the first quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock valued at $214,000 after buying an additional 2,824 shares during the period. Victory Capital Management Inc. bought a new stake in Paratek Pharmaceuticals during the first quarter valued at approximately $630,000. Nine Chapters Capital Management LLC bought a new stake in Paratek Pharmaceuticals during the first quarter valued at approximately $258,000. Bank of New York Mellon Corp increased its stake in Paratek Pharmaceuticals by 17.5% in the first quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock valued at $1,618,000 after buying an additional 12,505 shares during the period. Finally, Falcon Point Capital LLC bought a new stake in Paratek Pharmaceuticals during the first quarter valued at approximately $200,000. 77.36% of the stock is currently owned by institutional investors and hedge funds.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to analyst estimates of $7.50 million.

ILLEGAL ACTIVITY WARNING: “Candriam Luxembourg S.C.A. Has $5.47 Million Stake in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/candriam-luxembourg-s-c-a-has-5-47-million-stake-in-paratek-pharmaceuticals-inc-nasdaqprtk.html.

Several research firms have commented on PRTK. HC Wainwright boosted their target price on Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, April 21st. Raymond James Financial, Inc. began coverage on Paratek Pharmaceuticals in a report on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 target price on the stock. Finally, BidaskClub downgraded Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Paratek Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $37.44.

In other news, CFO Douglas W. Pagan sold 4,595 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $25.00, for a total value of $114,875.00. Following the completion of the sale, the chief financial officer now owns 51,000 shares of the company’s stock, valued at approximately $1,275,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Michael Bigham sold 5,075 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total value of $119,668.50. Following the completion of the sale, the chairman now directly owns 109,500 shares of the company’s stock, valued at approximately $2,582,010. The disclosure for this sale can be found here. Insiders sold a total of 21,960 shares of company stock valued at $524,342 in the last three months. Insiders own 4.90% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.